AR029825A1 - Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma - Google Patents

Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma

Info

Publication number
AR029825A1
AR029825A1 ARP010101538A ARP010101538A AR029825A1 AR 029825 A1 AR029825 A1 AR 029825A1 AR P010101538 A ARP010101538 A AR P010101538A AR P010101538 A ARP010101538 A AR P010101538A AR 029825 A1 AR029825 A1 AR 029825A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
same
production
composition
salt
Prior art date
Application number
ARP010101538A
Other languages
English (en)
Inventor
Rolf-Dieter Gabel
Walter Preis
Guenter Neugebauer
Alexander Wirl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029825(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR029825A1 publication Critical patent/AR029825A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con composiciones farmacéuticamente aceptables, que comprenden carvedilol o una sal del mismo farmacéuticamente aceptable, distribuida como una dispersion molecular en una concentracion superior a 5% (p/p), como así también a un procedimiento para la produccion de las mismas, y su utilizacion para la produccion de medicamentos para el tratamiento y/o profilaxis de enfermedades como hipertension, insuficiencia cardíaca o angina de pecho.
ARP010101538A 2000-04-03 2001-03-30 Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma AR029825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00107093 2000-04-03

Publications (1)

Publication Number Publication Date
AR029825A1 true AR029825A1 (es) 2003-07-16

Family

ID=8168348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101538A AR029825A1 (es) 2000-04-03 2001-03-30 Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma

Country Status (24)

Country Link
US (3) US20010036959A1 (es)
EP (1) EP1272179B1 (es)
JP (1) JP2003528915A (es)
KR (1) KR100478793B1 (es)
CN (1) CN1189171C (es)
AR (1) AR029825A1 (es)
AT (1) ATE450257T1 (es)
AU (2) AU2001256227B2 (es)
BR (1) BR0109779A (es)
CA (1) CA2401910C (es)
CZ (1) CZ20023625A3 (es)
DE (1) DE60140662D1 (es)
HR (1) HRP20020777A2 (es)
HU (1) HUP0300342A3 (es)
IL (1) IL151642A0 (es)
MA (1) MA26888A1 (es)
MX (1) MXPA02009725A (es)
NO (1) NO20024733L (es)
NZ (1) NZ521232A (es)
PL (1) PL358103A1 (es)
RU (1) RU2248204C2 (es)
WO (1) WO2001074357A1 (es)
YU (1) YU72602A (es)
ZA (1) ZA200207304B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
AU2002338726B2 (en) * 2001-09-28 2007-03-15 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US20050261335A1 (en) * 2002-05-03 2005-11-24 Wei Chen Carvedilol formulations
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
KR20140006111A (ko) * 2002-06-27 2014-01-15 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP1610768B1 (en) * 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
KR100486016B1 (ko) * 2003-07-09 2005-04-29 주식회사종근당 타크로리무스의 속용성 고체분산체 및 이의 제조방법
EP1663216B1 (en) 2003-08-29 2011-11-02 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
CN101869561A (zh) * 2003-08-29 2010-10-27 生命周期药物公司 含有他克莫司的改良释放组合物
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080138404A1 (en) * 2006-12-06 2008-06-12 Biovail Laboratories International S.R.L. Extended release formulations of carvedilol
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8889728B2 (en) * 2008-03-04 2014-11-18 Lupin Limited Stable pharmaceutical compositions of carvedilol
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011154009A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprising an active principle in an amorphous form and a porous adsorbent material
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
ES2227814T3 (es) * 1997-03-11 2005-04-01 Arakis Ltd. Formas de dosificacion que comprenden porciones separadas de enantiomeros r y s.
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
US6852337B2 (en) * 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation

Also Published As

Publication number Publication date
CN1189171C (zh) 2005-02-16
IL151642A0 (en) 2003-04-10
KR20030019339A (ko) 2003-03-06
CZ20023625A3 (cs) 2003-04-16
US20050271721A1 (en) 2005-12-08
EP1272179B1 (en) 2009-12-02
US20010036959A1 (en) 2001-11-01
PL358103A1 (en) 2004-08-09
RU2248204C2 (ru) 2005-03-20
HRP20020777A2 (en) 2004-12-31
HUP0300342A3 (en) 2005-07-28
NZ521232A (en) 2004-05-28
RU2002129571A (ru) 2004-03-27
ZA200207304B (en) 2003-12-11
CA2401910C (en) 2008-04-15
MXPA02009725A (es) 2003-03-27
AU2001256227B2 (en) 2005-09-01
AU5622701A (en) 2001-10-15
HUP0300342A2 (hu) 2003-06-28
EP1272179A1 (en) 2003-01-08
BR0109779A (pt) 2003-01-21
ATE450257T1 (de) 2009-12-15
DE60140662D1 (de) 2010-01-14
JP2003528915A (ja) 2003-09-30
NO20024733D0 (no) 2002-10-02
CA2401910A1 (en) 2001-10-11
KR100478793B1 (ko) 2005-03-24
WO2001074357A1 (en) 2001-10-11
MA26888A1 (fr) 2004-12-20
CN1420771A (zh) 2003-05-28
NO20024733L (no) 2002-10-02
US20030004205A1 (en) 2003-01-02
YU72602A (sh) 2005-03-15

Similar Documents

Publication Publication Date Title
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
PA8591701A1 (es) Derivados de pirrolopirimidina
AR023837A1 (es) 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
AR023129A1 (es) Composiciones para mejorar la fertilidad
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
CO5590913A2 (es) Terapia de combinacion antivirica
AR020287A1 (es) Preparaciones de una combinacion farmaceutica.
ECSP055844A (es) Nuevos compuestos triciclicos
ECSP003807A (es) Composiciones valdecoxib
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
BR0312453A (pt) Implante para o transporte e a liberação de agentes farmacologicamente ativos e processo para a produção do mesmo
UY28282A1 (es) Mediadores peptidicos del trasporte inverso de colesterol para el tratamiento de hipercolesterolemia
AR046143A1 (es) Composicion farmaceutica que contiene un derivado de tiourea con solubilidad y biodisponiblidad mejoradas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal